ORPHAN SYNERGY EUROPE-PHARMA (EPA:OSE) | WebDisclosure

Basculer en Français

10443	Companies
219247	Keywords
148701	Articles
115972	Press releases

Headlines Articles Press releases ORPHAN SYNERGY EUROPE-PHARMA

Home
Companies
ORPHAN SYNERGY EUROPE-PHARMA

PRESS RELEASE

published on 08/29/2025 at 08:00, 8 months 25 days ago

OSE Immunotherapeutics Reaffirms its Strategic Priorities and Publishes Shareholder Q&A to Restore Information Ahead of AGM
OSE Immunotherapeutics reaffirms strategic priorities with comprehensive Q&A document ahead of AGM. Company focuses on Tedopi® and Lusvertikimab programs for value creation

Strategic Priorities OSE Immunotherapeutics Lusvertikimab Shareholder Q&A Tedopi®
BRIEF

published on 08/25/2025 at 07:05, 8 months 29 days ago

OSE Immunotherapeutics : Nouvelle Gouvernance et Objectifs Stratégiques

Stratégie Gouvernance Actionnaires Biotechnologie Tedopi Et Lusvertikimab
BRIEF

published on 08/25/2025 at 07:05, 8 months 29 days ago

OSE Immunotherapeutics: New Governance and Strategic Objectives

Shareholders Biotechnology Governance Strategy Tedopi And Lusvertikimab
PRESS RELEASE

published on 08/25/2025 at 07:00, 8 months 29 days ago

OSE Immunotherapeutics Propose une Evolution de sa Gouvernance et Réaffirme ses Priorités Stratégiques à l’Approche de son Assemblée Générale Annuelle
OSE Immunotherapeutics propose une évolution de sa gouvernance et réaffirme ses priorités stratégiques. Assemblée Générale Annuelle le 30 septembre 2025 à Paris

Gouvernance Évolution Assemblée Générale Annuelle Priorités Stratégiques OSE Immunotherapeutics
PRESS RELEASE

published on 08/25/2025 at 07:00, 8 months 29 days ago

OSE Immunotherapeutics Proposes Governance Evolution and Reaffirms Strategic Priorities ahead of Annual General Meeting
OSE Immunotherapeutics announces proposed governance evolution and reaffirms strategic priorities ahead of Annual General Meeting. Company focuses on Tedopi® and Lusvertikimab to unlock full potential

Strategic Priorities Governance Evolution OSE Immunotherapeutics Lusvertikimab Tedopi
BRIEF

published on 08/20/2025 at 18:05, 9 months 3 days ago

OSE Immunotherapeutics Appoints Thomas Gidoin as CFO

Chief Financial Officer Strategic Planning Biotech Financing OSE Immunotherapeutics Thomas Gidoin
BRIEF

published on 08/20/2025 at 18:05, 9 months 3 days ago

OSE Immunotherapeutics nomme Thomas Gidoin au poste de directeur financier

Directeur Financier Planification Stratégique OSE Immunotherapeutics Financement Des Biotechnologies Thomas Gidoin
PRESS RELEASE

published on 08/20/2025 at 18:00, 9 months 3 days ago

OSE Immunotherapeutics Appoints Thomas Gidoin as Chief Financial Officer
OSE Immunotherapeutics appoints Thomas Gidoin as Chief Financial Officer, bringing deep expertise in capital markets and financial strategy to the company. Gidoin succeeds Anne-Laure Autret-Cornet

Chief Financial Officer Capital Markets Financial Strategy OSE Immunotherapeutics Thomas Gidoin
PRESS RELEASE

published on 08/20/2025 at 18:00, 9 months 3 days ago

OSE Immunotherapeutics nomme Thomas Gidoin au poste de Directeur Financier
Nomination de Thomas Gidoin comme nouveau Directeur Financier chez OSE Immunotherapeutics. Il apporte 15 ans d'expertise internationale en finance et gouvernance

Biotechnologie Finance Directeur Financier OSE Immunotherapeutics Thomas Gidoin
BRIEF

published on 07/02/2025 at 08:05, 10 months 21 days ago

OSE Immunotherapeutics Updates on Legal Proceedings

Transparency Shareholder Meeting Legal Proceedings OSE Immunotherapeutics Nantes Commercial Court

Accesswire

Published on 05/23/2026 at 19:45, 7 hours 48 minutes ago

Golden Minerals Announces Closing of Equity Financing
Published on 05/23/2026 at 03:15, 1 day ago

UraniumX Approved for Trading on the OTCQB Venture Market and Announces Board Change
Published on 05/23/2026 at 03:00, 1 day ago

Battery X Metals Reports Up to ~84 km Estimated Driving Range Increase Across Multiple BYD Electric Vehicles Following Next-Generation Patent-Pending Lithium-Ion Battery Rebalancing Trials, Demonstrating Performance Improvement Across the World’s Larges
Published on 05/23/2026 at 02:25, 1 day 1 hour ago

Battery X Metals Announces up to $2 Million Private Placement Financing and Initiative to Strengthen Balance Sheet
Published on 05/23/2026 at 02:25, 1 day 1 hour ago

Bolt Metals Completes 402 line-km MobileMT Survey at Northwind Property, Quebec

View all ACCESSWIRE

EQS Group

Published on 05/23/2026 at 16:30, 11 hours 3 minutes ago

HiFS 2026: Upgrading Four Major Digital Finance Solutions to Accelerate Financial Institutions Toward Agentic Banking
Published on 05/23/2026 at 15:57, 11 hours 36 minutes ago

EQS-Adhoc: Delivery Hero confirms approach by Uber Technologies’ with respect to potential takeover offer
Published on 05/22/2026 at 22:05, 1 day 5 hours ago

Abivax présente ses résultats financiers du T1 2026 et les données à trois ans de l’étude 108, un essai d’extension ouvert de phase 2a/2b évaluant l’obéfazimod après réduction de dose dans la RCH
Published on 05/22/2026 at 22:05, 1 day 5 hours ago

Abivax Presents Q1 2026 Financial Results and Reports Three-Year Interim Data from Study 108, a Phase 2a/2b Open-Label Extension Trial of Obefazimod Following Dose De-Escalation in Patients with UC
Published on 05/22/2026 at 19:51, 1 day 7 hours ago

Turkiye Garanti Bankasi A.S.: Brokerage Houses Warrants Redemption Prices

Les Echos

Published on 05/22/2026 at 19:35, 1 day 7 hours ago

PROJET D'EVOLUTION DE SA GOUVERNANCE ET LA NOMINATION D'UN PRESIDENT DU DIRECTOIRE PAR INTERIM
Published on 05/22/2026 at 18:05, 1 day 9 hours ago

Déclaration hebdomadaire d'opérations effectuées du 18 au 22 mai 2026
Published on 05/22/2026 at 18:05, 1 day 9 hours ago

Disclosure of transactions in own shares from May 18 to May 22, 2026
Published on 05/22/2026 at 12:52, 1 day 14 hours ago

Communiqué du Conseil d’administration – Assemblée Générale du 22 mai 2026
Published on 05/22/2026 at 12:52, 1 day 14 hours ago

Release from the Board of Directors - Shareholders’ Meeting of May 22, 2026

View all LES ECHOS COMFI WIRE